CYP450 Chart 5.2016

PL Detail-Document #320506
−This PL Detail-Document gives subscribers

additional insight related to the Recommendations published in−
PHARMACIST’S LETTER / PRESCRIBER’S LETTER
May 2016
Cytochrome P450 Drug Interactions

The characterization of drug interactions by metabolic pathways is complex. Just because a medication interacts with one substrate of a particular cytochrome P450
pathway does not mean it affects all substrates of that isozyme. Genetics, age, nutrition, stress, liver disease, hormones, and other endogenous chemicals also
influence drug metabolism. Additional influences on drug interactions include drug dosing (e.g., dose, timing, sequence, route of administration, duration of
therapy, etc), concomitant medications, potential for a concurrent pharmacodynamic interaction (e.g., gemfibrozil plus fluvastatin), and specific drug features
(narrow therapeutic index, high extraction ratio, side effect profile, multiple metabolic pathways). For example, most drugs metabolized by CYP2C8 have alternate
metabolic pathways, so inhibition of just one pathway might not be clinically important. It is prudent to use any combination with potential for interaction with
caution (e.g., conservative dosing, appropriate monitoring), especially those involving drugs with a narrow therapeutic index and/or potentially serious dose-
dependent side effects (e.g., chemotherapy, cardiac medications, anticonvulsants, etc). In the table that follows, italics denote those substrates, inhibitors, and
inducers involved in a pharmacokinetic drug interaction that is clinically evident and/or is associated with a strong drug interaction warning or recommendation for
specific intervention (e.g., specific dose alteration, laboratory monitoring, avoidance, etc) that may involve that isoenzyme. This table is not comprehensive, and
new information is constantly being identified. A medication might not be listed as a substrate of an enzyme that is a minor metabolic pathway for the medication, or
if there is only in vitro or weak evidence of that enzyme’s potential for a clinically significant drug interaction involving the medication. In addition, drugs that are
weak inhibitors or inducers of an enzyme might not be listed.
**Denotes strong inhibitors (>5-fold increase in exposure, or >80% decrease in clearance of substrate). *Denotes moderate inhibitors (>2 to <5-fold increase
in exposure, or 50% to 80% decrease in clearance of substrate). For many meds, strength of inhibition in vivo is undetermined.
—In addition to the references listed below, information from product labeling was also utilized.—
CYP1A2
--------Substrates-------- --------Inhibitors-------- --Inducers--
acetaminophen diphenhydramine mirtazapine ropivacaine acyclovir isoniazid carbamazepine
alosetron doxepin naproxen tasimelteon allopurinol kavab charbroiled food
amitriptyline duloxetine olanzapine theophylline amiodarone methoxsalen* lansoprazole
aprepitant erlotinib ondansetron tizanidine caffeine mexiletine* modafinil
asenapine febuxostat palonosetron triamterene cimetidine norfloxacin montelukast
axitinib flutamide pirfenidone verapamil ciprofloxacin** oral contraceptives* omeprazole
bendamustine fluvoxamine pomalidomide vorapaxar citalopram osimertinib phenobarbital
bortezomib frovatriptan propafenone (R)-warfarin disulfiram propafenone phenytoin
caffeine imipramine propranolol zileuton echinacea propranolol primidone
chlordiazepoxide lidocaine ramelteon zolmitriptan ethinyl terbinafine rifampin
cinacalcet lomitapide rasagiline estradiol* ticlopidine ritonavir
clomipramine melatonin riluzole famotidine vemurafenib smoking
clopidogrel methadonea riociguat fluvoxamine** verapamil St. John’s wort
clozapine mexiletine roflumilast imipramine zafirlukast teriflunomide
cyclobenzaprine ropinirole zileuton* tipranavir
More. . .
Copyright © 2016 by Therapeutic Research Center
3120 W. March Lane, Stockton, CA 95219 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
www.PharmacistsLetter.com ~ www.PrescribersLetter.com ~ www.PharmacyTechniciansLetter.com
(PL Detail-Document #320506: Page 2 of 8)
CYP2C8
amiodarone ibuprofen rosiglitazone abiraterone montelukast lumacaftor
cabazitaxel isotretinoin selexipag atazanavir nicardipine nilotinib
carbamazepine lapatinib sitagliptin avanafil nilotinib rifampin
chloroquine lomitapide torsemide clopidogrel* pazopanib rifapentine
dabrafenib loperamide treprostinil deferasirox quercetin Note: CYP50 inducers tend to be
dasabuvir montelukast tretinoin fenofibrate sorafenib “broad spectrum,” so inducers of other
diclofenac olodaterol verapamil fluvoxamine teriflunomide isozymes (e.g., phenobarbital, St.
enzalutamide paclitaxel Viekira Pak gemfibrozil** trimethoprim John’s wort) might also induce
febuxostat pioglitazone warfarin ketoconazole vemurafenib CYP2C8.5
fluvastatin pitavastatin zopiclone lapatinib vilazodone
Holkira Pak ponatinib lumacaftor vortioxetine
repaglinide
CYP2C9
amitriptyline glyburide ramelteon amiodarone* leflunomide aprepitant
belinostat ibuprofen rosiglitazone avanafil lovastatin bosentan
bosentan indomethacin ruxolitinib capecitabine lumacaftor carbamazepine
brivaracetam irbesartan sertraline ceritinib metronidazole dabrafenib
carvedilol isotretinoin sildenafil clopidogrel miconazole* enzalutamide
celecoxib losartanc sulfamethoxazole cotrimoxazole milk thistleb lumacaftor
chlorpropamide marijuana tamoxifen cranberryb modafinil nilotinib
cyclophosphamide mefenamic acid tolbutamide delavirdine nateglinide phenobarbital
desogestrelc meloxicam torsemide efavirenz nilotinib phenytoin
diclofenac methadonea valproic acid etravirine oritavancin primidone
diphenhydramine montelukast valsartan fenofibrate oxandrolone* rifampin
doxepin naproxen vardenafil fluconazole* pomegranateb rifapentine
dronabinol nateglinide vismodegib fluorouracil sulfamethoxazole ritonavir
etravirine netupitant voriconazole fluoxetine sulfinpyrazone St. John’s wortb
febuxostat olodaterol (S)-warfarin fluvastatin tigecycline
fluoxetine ospemifene zafirlukast gemfibrozil valproic acid
flurbiprofen phenobarbital zileuton ginkgob vemurafenib
fluvastatin phenytoin imatinib vismodegib
formoterol pitavastatin ivacaftor voriconazole
glimepiride piroxicam kavab vortioxetine
glipizide zafirlukast
More. . .
CYP2C19
ambrisentan lapatinib armodafinil letrozole aprepitant
amitriptyline lomitapide avanafil luliconazole carbamazepine
aprepitant methadonea bortezomib moclobemide* enzalutamide
axitinib moclobemide chloramphenicol modafinil ginkgob
bortezomib nelfinavir cimetidine nicardipine lumacaftor
brivaracetam nilutamide citalopram omeprazole* phenobarbital
carisoprodol omeprazole clomipramine oxcarbazepine phenytoin
cilostazol ospemifene delavirdine telmisartan primidone
citalopram pantoprazole efavirenz ticlopidine** rifampin
clobazam pentamidine eslicarbazepine* topiramate St. John’s wort
clomipramine phenobarbital esomeprazole* valproic acid tipranavir/ritonavir
clopidogrelc phenytoin ethinyl estradiol vismodegib
cyclophosphamide primidone etravirine voriconazole*
dexlansoprazole progesterone felbamate vortioxetine
diazepam proguanilc fenofibrate
diphenhydramine propranolol fluconazole**
doxepin rabeprazole fluoxetine*
escitalopram sertraline fluvoxamine**
esomeprazole thioridazine imipramine
etravirine tofacitinib isoniazid
flibanserin valproic acid kavab
formoterol vilazodone lansoprazole
imipramine voriconazole
lansoprazole (R)-warfarin
More. . .
CYP2D6
--------Substrates-------- -----Inhibitors----- --Inducers--
amitriptyline fesoterodine perphenazine abiraterone iloperidone dexamethasone
amphetamine fingolimod pimozide amiodarone imatinib rifampin
aripiprazole flecainide pomegranate amitriptyline imipramine
asenapine fluoxetine ponatinib asenapine kavab
atomoxetine fluphenazine propafenone avanafil lorcaserin
avanafil fluvoxamine propranolol bupropion** lumefantrine
brexpiprazole formoterol ranolazine celecoxib metoclopramide
cariprazine galantamine risperidone chloramphenicol mirabegron*
carvedilol haloperidol ritonavir chloroquine moclobemide
cevimeline hydrocodone tamoxifenc chlorpheniramine nicardipine
chloroquine iloperidone tetrabenazine chlorpromazine nilotinib
chlorpheniramine imipramine thioridazine cimetidine panobinostat
chlorpromazine maprotiline timolol cinacalcet* paroxetine**
ciclesonide (des- meperidine tolterodine citalopram pazopanib
ciclesonide [active methadonea tramadolc clemastine peginterferon alpha-2b
metabolite]) methamphetamine trazodone clobazam perphenazine
cinacalcet metoclopramide venlafaxine clozapine pindolol
clomipramine metoprolol vilazodone cobicistat pomegranate
clozapine mexiletine vortioxetine cocaine promethazine
cobicistat mirabegron darifenacin* propafenone
codeinec mirtazapine darunavir/ritonavir propranolol
cyclobenzaprine nebivolol desipramine quinidine**
darifenacin netupitant desvenlafaxine quinine
desipramine nortriptyline diphenhydramine ranitidine
dextromethorphan olanzapine dronedarone* ranolazine
diphenhydramine ondansetron duloxetine* ritonavir
dolasetron oxycodone eliglustat rolapitant
donepezil palonosetron escitalopram sertraline*
doxepin paroxetine everolimus terbinafine*
doxorubicin fluoxetine** thioridazine
duloxetine fluphenazine ticlopidine
eliglustat goldenseal tripelennamine
haloperidol tipranavir/ritonavir
hydroxychloroquine vemurafenib
hydroxyzine venlafaxine
More. . .
CYP3A4
--------Substrates------
abiraterone cabazitaxel dexamethasone fesoterodine lopinavir/ritonavir ospemifene salmeterol tramadol
acetaminophen cabozantinib dexlansoprazole finasteride loratadinec oxybutynin saquinavir trazodone
ado-trastuzumab canagliflozin dextromethorphan fingolimod loperamide oxycodone saxagliptin tretinoin
emtansine carbamazepine diazepam flibanserin losartan paclitaxel selexipag triazolam
alfentanil cariprazine dienogest flutamide lovastatin palonosetron sertraline trimipramine
alecensa ceritinib dihydroergotamine fluticasone lumefantrine paliperidone sildenafil ulipristal
alfuzosin cevimeline diltiazem fosamprenavir lurasidone panobinostat silodosin vandetanib
aliskiren chloroquine disopyramide fulvestrant macitentan pazopanib simeprevir vardenafil
alitretinoin cilostazol docetaxel galantamine maraviroc perampanel simvastatin vemurafenib
almotriptan ciclesonide (des- dofetilide Genvoya marijuana pimozide sirolimus venlafaxine
alprazolam ciclesonide [active dolasetron guanfacine methadonea palbociclib sitagliptin verapamil
ambrisentan metabolite]) dolutegravir haloperidol methylprednisolone pomalidomide solifenacin Viekira Pak
amitriptyline cinacalcet domperidone Holkira Pak midazolam ponatinib sonidegib vilanterol
amiodarone cisapride donepezil hydrocodone mifepristone pioglitazone sorafenib vilazodone
amlodipine citalopram doxepin hydrocortisone mirabegron prednisolone sunitinib vinblastine
apixaban clarithromycin doxorubicin ibrutinib mirtazapine prednisone suvorexant vincristine
apremilast clindamycin dronedarone idelalisib modafinil (prednisolone [active tacrolimus vinorelbine
aprepitant clomipramine dutasteride ifosfamidec mometasone metabolite]) tadalafil vismodegib
aripiprazole clonazepam efavirenz iloperidone montelukast progesterone/ tamoxifen vorapaxar
armodafinil clopidogrel eletriptan imatinib naloxegol progestins tasimelteon voriconazole
artemether clozapine eliglustat imipramine nateglinide propafenone Technivie vortioxetine
asenapine cobicistat elvitegravir indacaterol nefazodone quetiapine telithromycin (R)-warfarin
atazanavir cobimetinib enzalutamide indinavir** nelfinavir quinidine teniposide zaleplon
atorvastatin cocaine eplerenone isavuconazonium netupitant quinine testosterone Zepatier
avanafil colchicine ergotamine irinotecan nevirapine rabeprazole tiagabine zileuton
axitinib conivaptan erlotinib isotretinoin nicardipine ramelteon ticagrelor ziprasidone
beclomethasone crizotinib erythromycin isradipine nifedipine ranolazine tinidazole zolmitriptan
bedaquiline cyclobenzaprine escitalopram itraconazole nilotinib regorafenib tipranavir zolpidem
belinostat cyclophosphamidec esomeprazole ivabradine nimodipine repaglinide tofacitinib zonisamide
bexarotene cyclosporine estrogens ivacaftor nisoldipine riosiguat tolterodine
boceprevir dabrafenib eszopiclone ixabepilone nintedanib rifabutin tolvaptan
bosentan daclatasvir ethinyl estradiol ixazomib norethindrone rifaximin toremifene
bosutinib dapsone ethosuximide ketoconazole nortriptyline rilpivirine trabectedin
brentuximab darifenacin etonogestrel lapatinib olodaterol risperidone
brexpiprazole darunavir etoposide lansoprazole olaparib ritonavir
bromocriptine dasatinib etravirine lenvatinib omeprazole rivaroxaban
budesonide delavirdine exemestane letrozole ondansetron roflumilast
buprenorphine desogestrel everolimus levonorgestrel oral contraceptives rolapitant
buspirone (etonogestrel [active felodipine lidocaine osimertinib romidepsin
metabolite]) fentanyl linagliptin ruxolitinib
lomitapide
More. . .
CYP3A4
--Inhibitors-- --Inducers--
amiodarone danazol goldensealb nilotinib aprepitant nafcillin
amlodipine delavirdine grapefruit** osimertinib armodafinil nevirapine
aprepitant* diltiazem* Holkira Pak** palbociclib bosentan oritavancin
atazanavir* darunavir/ritonavir* indinavir** pazopanib carbamazepine oxcarbazepine
avanafil dronedarone* imatinib* pomegranateb clobazam perampanel
boceprevir** echinaceab isoniazid posaconazole** dabrafenib phenobarbital
bicalutamide erythromycin* itraconazole** quinine dexamethasone phenytoin
bromocriptine ethinyl estradiol kavab ranolazine echinaceab pioglitazone
ceritinib everolimus ketoconazole** ritonavir** efavirenz prednisone
chloramphenicol fluconazole* idelalisib** saquinavir/ritonavir** enzalutamide primidone
cimetidine fluoxetine lansoprazole Schisandra eslicarbazepine rifabutin
ciprofloxacin* fluvoxamine luliconazole sphenantherab etravirine rifampin
clarithromycin** fosamprenavir* lapatinib Synercid felbamate rifapentine
cobicistat Genvoya lomitapide tamoxifen flutamide rifaximin
conivaptan** ginkgob lopinavir/ritonavir** Technivie** fosamprenavir ritonavir
crizotinib* mifepristone telithromycin** garlic supplementsb rufinamide
crofelemer mirabegron ticagrelor griseofulvin St. John’s wort
cyclosporine nefazodone** tipranavir/ritonavir lumacaftor topiramate
nelfinavir** valproic acid modafinil
netupitant* verapamil*
nicardipine Viekira Pak**
nifedipine voriconazole**
zafirlukast
zileuton
a. Methadone: there is evidence of clinically important methadone interactions mediated through CYP2B6.27 For more information on methadone drug interactions, see our PL
Chart, Methadone for Pain: Focus on Safety.
b. Based on preliminary or contradictory evidence. Clinical significance is unknown.24
c. Prodrug activated via this enzyme.11,14,30-36
Users of this PL Detail-Document are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making
clinical judgments based on the content of this document. Our editors have researched the information with input from experts, government agencies, and national
organizations. Information and internet links in this article were current as of the date of publication.
More. . .
Project Leader in preparation of this PL Detail- g/ucm093664.htm#PgpTransport. (Accessed

Document: Melanie Cupp, Pharm.D., BCPS February 26, 2016).
14. Clinical Pharmacology [database online]. Tampa,
FL: Gold Standard, Inc.; 2016.
References http://www.clinicalpharmacology.com. (Accessed
1. Lemke TL, Williams DA, Roche VF, Zito SW. Eds. February 26, 2016).
Foye’s Principles of Medicinal Chemistry. 7th ed. 15. Yano R, Tani D, Watanabe K, et al. Evaluation of
Philadelphia, PA: Lippincott Williams & Wilkins; potential interaction between vinorelbine and
2013. clarithromycin. Ann Pharmacother 2009;43:453-8.
2. Relling MV, Pui CH, Sandlund JT, et al. Adverse 16. Stout SM, Cimino NM. Exogenous cannabinoids as
effect of anticonvulsants on efficacy of chemotherapy substrates, inhibitors, and inducers of human drug
for acute lymphoblastic leukaemia. Lancet metabolizing enzymes: a systematic review. Drug
2000;356:285-90 [abstract]. Metab Rev 2014;46:86-95.
3. Horn JR, Hansten PD. Get to know an enzyme: 17. Unterecker S, Reif A, Hempel S, et al. Interaction of
CYP1A2. Pharmacy Times. November 1, 2007. valproic acid and the antidepressant drugs doxepin
http://www.pharmacytimes.com/publications/issue/20 and venlafaxine: analysis of therapeutic drug
07/2007-11/2007-11-8279. (Accessed February 28, monitoring data under naturalistic conditions. Int Clin
2016). Psychopharmacol 2014;29:206-11.
4. Haslemo T, Refsum H, Molden E. The effect of 18. Miguel C, Albuquerque E. Drug interaction in
ethinylestradiol-containing contraceptives on the psycho-oncology: antidepressants and
serum concentration of olanzapine and N-desmethyl antineoplastics. Pharmacology 2011;88:333-9.
olanzapine. Br J Clin Pharmacol 2011;71:611-5. 19. Korhonen T, Tolonen A, Uusitalo J, et al. The role of
5. Horn JR, Hansten PD. Get to know an enzyme: CYP2C and CYP3A in the disposition of 3-keto-
CYP2C8. Pharmacy Times. December 7, 2011. desogestrel after administration of desogestrel. Br J
http://www.pharmacytimes.com/publications/issue/20 Clin Pharmacol 2005;60:69-75.
11/December2011/Get-to-Know-an-Enzyme- 20. Horn JR, Hansten PD. Get to know an enzyme:
CYP2C8-. (Accessed February 28, 2016). CYP3A. Pharmacy Times Sept 2008.
6. Indiana University Department of Medicine. Clinical http://www.hanstenandhorn.com/hh-article09-08.pdf.
Pharmacology. P450 drug interaction table. (Accessed March 24, 2016).
http://medicine.iupui.edu/clinpharm/ddis/table.aspx. 21. Vaidyanathan S, Jarugula V, Dieterich HA, et al.
(Accessed February 26, 2016). Clinical pharmacokinetics and pharmacodynamics of
7. Horn JR, Hansten PD. Get to know an enzyme: aliskiren. Clin Pharmacokinet 2008;47:515-31.
CYP2C9. Pharmacy Times. March 2008. 22. PL Detail-Document, Calcium Channel Blocker-
http://www.pharmacytimes.com/publications/issue/20 Macrolide Interaction. Pharmacist’s
08/2008-03/2008-03-8462. (Accessed February 29, Letter/Prescriber’s Letter. January 2014.
2016). 23. Geraci MJ, McCoy SL, Crum PM, Patel RA.
8. Horn JR, Hansten PD. Get to know an enzyme: Antipsychotic-induced priapism in an HIV patient: a
CYP2C19. Pharmacy Times. May 1, 2008. cytochrome P450-mediated drug interaction. Int J
http://www.pharmacytimes.com/publications/issue/20 Emerg Med 2010;3:81-4.
08/2008-05/2008-05-8538. (Accessed March 9, 24. Jellin JM, Gregory PJ, et al. Natural Medicines
2016). Comprehensive Database.
9. Rindone JP, Bryan G 2nd. Phenytoin toxicity http://www.naturaldatabase.com. (Accessed
associated with ticlopidine administration. Arch February 29, 2016).
Intern Med 1996;156:1113. 25. Hamelin BA, Bouayad A, Drolet B, et al. In vitro
10. Horn JR, Hansten PD. Get to know an enzyme: characterization of cytochrome P450 2D6 inhibition
CYP2D6. Pharmacy Times. July 1, 2008. by classic histamine H1 receptor antagonists. Drug
http://www.pharmacytimes.com/publications/issue/20 Metab Dispos 1998;26:536-9.
08/2008-07/2008-07-8624. (Accessed March 23, 26. Molden E, Spigset O. [Interactions between
2016). metoprolol and antidepressants]. Tidsskr Nor
11. Ortiz de Montellano PR. Cytochrome P450-activated Laegeforen 2011;131:1777-9 [abstract; article in
prodrugs. Future Med Chem 2013;5:213-28. Norwegian].
12. Spina E, Pisani F, de Leon J. Clinically significant 27. Chang Y, Fang WB, Lin S, Moody DE. Stereo-
pharmacokinetic drug interactions of antiepileptic selective metabolism of methadone by human liver
drugs with new antidepressants and new microsomes and cDNA-expressed cytochrome
antipsychotics. Pharmacol Res 2016;106:72-86. P450s: a reconciliation. Basic Clin Pharmacol
13. U.S. Food and Drug Administration. Drug Toxicol 2011;108:55-62.
development and drug interactions: table of 28. Leppert W. The role of methadone in cancer pain
substrates, inhibitors and inducers. October 27, treatment-a review. Int J Clin Pract 2009;7:1095-
2014. 109.
http://www.fda.gov/Drugs/DevelopmentApprovalProc
ess/DevelopmentResources/DrugInteractionsLabelin
More. . .
th
29. Bebawi E, Jouni SS, Tessier AA, et al. A metoprolol- 10 ed. Philadelphia, PA: Lippincott Williams &
terbinafine combination induced bradycardia. Eur J Wilkins, 2013:1949-82.
Drug Metab Pharmacokinet 2015;40:295-9. 41. Leppert W. The role of methadone in cancer pain
30. PL Detail-Document, Proton pump inhibitor and treatment-a review. Int J Clin Pract 2009;7:1095-
Plavix interaction: an update. Pharmacist’s 109.
Letter/Prescriber’s Letter. May 2013. 42. Granfors MT, Backman JT, Laitila K, Neuvonen PJ.
31. Lotsch J, Geisslinger G, Tegeder I. Genetic Oral contraceptives containing ethinyl estradiol and
modulation of the pharmacological treatment of pain. gestodene markedly increase plasma concentrations
Pharmacol Ther 2009;124:168-84. and effects of tizanidine by inhibiting cytochrome
32. de Jonge ME, Huitema AD, Holtkamp MJ, et al. P450 1A2. Clin Pharmacol Ther 2005;78:400-11.
Aprepitant inhibits cyclophosphamide bioactivation 43. Self TH, Chrisman CR, Finch CK. Asthma. In:
and thiotepa metabolism. Cancer Chemother Alldredge BK, Corelli RL, Ernst ME, et al, editors.
Pharmacol 2005;56:370-8. Koda-Kimble & Young’s Applied Therapeutics: the
th
33. Kerbusch T, Jansen RL, Mathot RA, et al. Clinical Use of Drugs. 10 ed. Philadelphia, PA:
Modulation of the cytochrome P450-mediated Lippincott Williams & Wilkins, 2013:565-600.
metabolism of ifosfamide by ketoconazole and 44. Naccarato M, Yoong D, Kovacs C, Gough K. A case
rifampin. Clin Pharmacol Ther 2001;70:132-41. of a potential drug interaction between clobazam and
34. PL Detail-Document, Tamoxifen and SSRIs: is there etravirine-based antiretroviral therapy. Antivir Ther
an interaction? Pharmacist’s Letter/Prescriber’s 2012;589-92 [abstract].
Letter. July 2009. 45. Tarumi Y, Pereira J, Watanabe S. Methadone and
35. Tirkkonen T, Laine K. Drug interactions with the fluconazole: respiratory depression by drug
potential to prevent prodrug activation as a common interaction. J Pain Symptom Manage 2002;23:148-
source of irrational prescribing in hospital inpatients. 53.
Clin Pharmacol Ther 2004;76:639-47. 46. Yu KS, Yim DS, Choo JY, et al. Effect of
36. Laugesen S, Enggaard TP, Pedersen RS, et al. omeprazole on the pharmacokinetics of
Paroxetine, a cytochrome P450 2D6 inhibitor, moclobemide according to the genetic polymorphism
diminishes the stereoselective O-demethylation and of CYP2C19. Clin Pharmacol Ther 2001;69:266-73.
reduces the hypoalgesic effect of tramadol. Clin 47. Carrillo JA, Ramos SI, Herraiz AG, et al.
Pharmacol Ther 2005;77:312-23. Pharmacokinetic interaction of fluvoxamine and
37. Adetunji B, Basil B, Matthews M, Osinowo T. Should thioridazine in schizophrenic patients. J Clin
the Physician’s Desk Reference contraindicate the Psychopharmacol 1999;19:494-9 [abstract].
use of chlorpromazine-fluoxetine combination? A 48. Kapil RP, Friedman K, Cipriano A, et al. Effects of
case report. J Clin Psychopharmacol 2006;26:438. paroxetine, a CYP2D6 inhibitor, on the
38. Panel on Antiretroviral Guidelines for Adults and pharmacokinetic properties of hydrocodone after
Adolescents. Guidelines for the use of antiretroviral coadministration with a single-entity, once-daily,
agents in HIV-1-infected adults and adolescents. extended-release hydrocodone tablet. Clin Ther
Department of Health and Human Services. March 2015;37:2286-96.
11, 2016. http://aidsinfo.nih.gov. (Accessed March 49. Akamine Y, Yasui-Furukori N, Ieiri I, Uno T.
11, 2016). Psychotropic drug-drug interactions involving p-
39. Gillman PK. Tricyclic antidepressant pharmacology glycoprotein. CNS Drugs 2012;26:959-73.
and therapeutic drug interactions updated. Br J 50. Horn JR, Hansten P. Drug interactions: beware of
Pharmacology 2007;151:737-48. CYP2D6 inhibitors in patients taking tamoxifen.
40. Finley PR, Lee KC. Mood disorders I: major Pharmacy Times. March 2009.
depressive disorders. In: Alldredge BK, Corelli RL, http://www.pharmacytimes.com/publications/issue/20
Ernst ME, et al, editors. Koda-Kimble & Young’s 09/2009-03/2009-03-10041. (Accessed April 7,
Applied Therapeutics: the Clinical Use of Drugs. 2016).
Cite this document as follows: PL Detail-Document, Cytochrome P450 Drug Interactions. Pharmacist’s
Letter/Prescriber’s Letter. May 2016.
Evidence and Recommendations You Can Trust…

3120 West March Lane, Stockton, CA 95219 ~ TEL (209) 472-2240 ~ FAX (209) 472-2249
Copyright  2016 by Therapeutic Research Center
Subscribers to the Letter can get PL Detail-Documents, like this one,

on any topic covered in any issue by going to www.PharmacistsLetter.com,
www.PrescribersLetter.com, or www.PharmacyTechniciansLetter.com

CYP450 Chart 5.2016

Загружено:

Сведения о документе

Авторское право

Доступные форматы

Поделиться этим документом

Поделиться или встроить документ

Параметры публикации

Этот документ был вам полезен?

Это неприемлемый материал?

Авторское право:

Доступные форматы

CYP450 Chart 5.2016

Загружено:

Авторское право:

Доступные форматы

PL Detail-Document #320506

−This PL Detail-Document gives subscribers

Cytochrome P450 Drug Interactions

Project Leader in preparation of this PL Detail- g/ucm093664.htm#PgpTransport. (Accessed

Evidence and Recommendations You Can Trust…

Subscribers to the Letter can get PL Detail-Documents, like this one,

Вам также может понравиться